Reuters logo
CORRECTED-Kite Pharma's lead cancer therapy shows promise in study
August 25, 2014 / 9:06 PM / 3 years ago

CORRECTED-Kite Pharma's lead cancer therapy shows promise in study

(Corrects paragraph 4 to change share price to $30.15 from $33.33)

Aug 25 (Reuters) - Drug developer Kite Pharma Inc said its experimental cancer therapy showed potential in treating patients in an early-stage study.

The company’s lead drug, KTE-C19, is being developed to fight an aggressive form of blood cancer.

The immunotherapy involves genetically modifying a patient’s cells to target a protein found on the surface of some lymphoma and leukemia cells.

Kite’s shares were up 35.2 percent at $30.15 in extended trading. (Reporting by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below